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The authors regret that in the original version of their paper, they mistakenly used the phrase OVA-expressing cells instead of OVA-secreting 
cells in parts of the text and cited reference Boissonnas et al. (2007. http://dx.doi.org/10.1084/jem.20061890) instead of Zeelenberg et al. 
(2008. http://dx.doi.org/10.1158/0008-5472.CAN-07-3163) and Sedlik et al. (2014. http://dx.doi.org/10.3402/jev.v3.24646). The Results 
and discussion paragraph containing the corrected references and full bibliographic information appear below:
“To address the possible role of Sec22b-dependent antigen cross-presentation in tumor immunotherapy by checkpoint blocking antibodies, we 
used a less-immunogenic tumor, OVA-secreting MCA-101 (Zeelenberg et al., 2008; Sedlik et al., 2014). This tumor is well controlled by 
antibodies against CTLA-4 or PD-1 (Gubin et al., 2014). Sec22b−/− and Sec22b+/+ mice were injected with tumor cells and received or did 
not receive anti–PD-1 treatment, as described previously (Gubin et al., 2014). As expected, treatment with anti–PD-1 induced tumor rejection 
in Sec22b+/+ littermates (Fig. 4 E). In contrast, Sec22b−/− mice failed to respond to anti–PD-1 treatment, both in terms of tumor growth and 
survival (Fig. 4, F and G). Consistently, treatment with anti–PD-1 induced an anti-OVA immune response in littermates, but not in Sec22b−/− 
mice, when analyzed by T cell restimulation and subsequent secretion of IFN-γ (Fig. 4 H and Fig. S3 B).”
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